Skip to main content
AHR logo

AHR · American Healthcare REIT, Inc.

Track AHR — free
$57.78 -0.86 (-1.47%) At close · Nov 13
Market Cap
$13.41B
Shares
232.07M
Volume · Nov 13 2.58M Avg daily vol (3M) 3.1M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$57.78 Open$58.97 Day$57.54–59.00 52W close$45.69–59.39 Avg vol 30d3.2M Short int33.7M · 14.5% of shares · 10.3d Short vol42% Last earningsNov 6, 2026 DataFeb 2024–Nov 2026 Filing10-Q · Nov 6

Up next

Feb 26, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 6
Current report 8-K
$1,750,000,000 ATM Common Stock Offering Launched

American Healthcare REIT, Inc. launched a $1,750,000,000 ATM common stock offering on November 6, 2026, terminating its prior program with approximately $170,134,000 remaining unsold.

Entered into a material agreement Read from the first part of this long document
2 source passages
On November 6, 2026, we and American Healthcare REIT Holdings, LP, or our Operating Partnership, entered into an ATM Equity Offering Sales Agreement, or the Sales Agreement, with BofA Securities, Inc., Citigroup Global Markets Inc., Citizens JMP Securities, LLC, Credit Agricole Securities (USA) Inc., Fifth Third Securities, Inc., KeyBanc Capital Markets Inc., Morgan Stanley & Co. LLC, RBC Capital Markets, LLC, Regions Securities LLC and Truist Securities, Inc., or each, an Agent, and, collectively, the Agents, and the Forward Purchasers (as defined below), providing for the offer and sale of shares of our common stock, $0.01 par value per share, or Common Stock, having an aggregate gross sales price of up to $1,750,000,000, or the Shares, through the Agents, as our sales agents or, if applicable, as forward sellers, or directly to the Agents as principals. Upon entry into the Sales Agreement, we terminated our prior at-the-market offering program and the related ATM Equity Offering Sales Agreement, dated as of February 27, 2026, or the Prior Sales Agreement, entered into with the agents and forward purchasers named therein. At the time of the termination of the Prior Sales Agreement, approximately $170,134,000 remained unsold under the Prior Sales Agreement. Open the document at this passage
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises as portfolio reaches 366 buildings

American Healthcare REIT, Inc. reported nine-month 2026 revenue of $2,067,173 thousand, up from $1,656,043 thousand in 2025, driven by acquisitions and higher resident occupancy. As of September 30, 2026, its portfolio comprised 366 buildings totaling approximately 25,437,000 square feet.

Revenue $742.15M ▲ 29.5% Net income $31.21M ▼ 44.2% Diluted EPS $0.14 ▼ 57.6%
Read from the MD&A section
5 source passages
American Healthcare REIT, Inc., a Maryland corporation, is a self-managed REIT that acquires, owns and operates a diversified portfolio of clinical healthcare real estate properties As of September 30, 2026, we owned and/or operated 366 buildings and ISHC, which represent in total approximately 25,437,000 square feet of gross leasable area, or GLA, for an aggregate contract purchase price of $7,426,645,000. Revenues by reportable segment consisted of the following for the periods presented below (in thousands): Nine Months Ended September 30, | 2026 | 2025 Total revenues | 742,149 | 572,937 | 2,067,173 | 1,656,043 Open the document at this passage
Nov 6
Earnings call
Raises 2026 NFFO guidance as same-store NOI reaches 13.8 percent

American Healthcare REIT raised full-year 2026 NFFO per diluted share guidance to $223 to $226 from $215 to $219 after third-quarter same-store NOI grew 13.8 percent; net debt to annualized adjusted EBITDA improved to 1.9 times.

Read from the first part of this long document
4 source passages
Good morning. Thank you for joining us for American Healthcare REIT's third quarter 2026 earnings conference call. Total same-store NOI growth of 13.8 percent Given these results, we are now raising full-year 2026 NFFO per diluted share guidance to a range of $223 to $226, up from our prior range of $215 to $219. Net debt to annualized adjusted EBITDA improved to 1.9 times, half a turn lower sequentially and 1.6 turns lower than a year ago. Open the document at this passage
Nov 5
Current report 8-K
Raises 2026 Guidance After 13.8% Same-Store NOI Growth

American Healthcare REIT, Inc. reported third-quarter NFFO of $0.58 per diluted share and 13.8% Same-Store NOI growth, raising 2026 NFFO guidance to $2.23 to $2.26 and Same-Store NOI growth guidance to 12.0% to 14.0%.

Financial results, Regulation FD disclosure Read from the first part of this long document
4 source passages
American Healthcare REIT, Inc. is announcing today its third quarter 2026 results and increasing full year 2026 guidance. Normalized Funds From Operations attributable to controlling interest (“NFFO”) of $0.58 per diluted share. Achieved total portfolio Same-Store Net Operating Income (“Same-Store NOI”) growth of 13.8%. Increased total portfolio Same-Store NOI growth guidance to 12.0% to 14.0% and NFFO per diluted share guidance to $2.23 to $2.26 for the year ending December 31, 2026. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$2.67B
Trailing 12 months
Net income (TTM)
$96.31M
Trailing 12 months
Revenue growth YoY
+29.5%
Year over year
Operating margin
20.2%
Trailing 12 months
P / FFO
37.4×
Company-stated · TTM · reciprocal yield 2.7%
P / E (TTM)
115.6
Trailing earnings · reciprocal yield 0.9%
Return on invested capital
—
Trailing 12 months
Net cash
$222.77M
Latest balance sheet
Dividend yield
1.7%
Trailing 12 months
Shares change YoY
+28.2%
Year over year · more shares
Price change (1Y)
+19.8%
Trailing year
Short interest
14.5%
Latest settlement · 10.3 days to cover
View all 129 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Low
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +11%
above
Price vs 50-day avg +8%
above
RSI (14) 63
neutral
MACD trend Positive
52-week position 88%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +9%
trailing
6-month return +13%
trailing
YTD return +23%
this year
Relative strength +13%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $53 › 200d $52 — 50d above 200d
Institutional flow Accumulating
515 of 579 funds reported for Sep 30 · net +26.9M sh shares · +57 new
Insider flow Distributing
Net -$226.4K over 90 days · 100% sells
Short interest Rising
14.51% of shares out · ▲ +1.5% MoM · 10.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
579 holders — near 2-yr high, broad support
Squeeze score 73
high risk · 0–100
Fundamentals
Strong
Revenue growth +9%
Y/Y
EPS growth +245%
Y/Y
Valuation P/E 115.6
rich
Quant / Vol
risk profile
Low
Volatility 26%
annualized · 1-yr
Max drawdown −14%
past year
ATR 2.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 6, 2026
full-year 2026
NFFO per diluted share Non-GAAP $223.00 – $226.00
NFFO per diluted share growth Non-GAAP at least 30%
NFFO per diluted share Non-GAAP Raised $223.00 – $226.00
Nov 5, 2026 $2.23 – $2.26 changed to Nov 6, 2026 $223.00 – $226.00
Trilogy same-store NOY growth 14.5% – 16.5%
SHOT same-store NOI growth 23% – 26%
SHOT same-store NOY growth 23% – 26%
TripleNet Properties same-store NOY growth 2.5% – 3.5%
Outpatient Medical same-store NOY growth 0.5% – 1%
full year
Total portfolio same-store NOI growth Raised 12% – 14%
Aug 7, 2026 11% – 13% changed to Nov 6, 2026 12% – 14%
Trilogy same-store NOI growth Raised 14.5% – 16.5%
May 8, 2026 11% – 15% changed to Nov 6, 2026 14.5% – 16.5%
SHOP same-store NOI growth Raised 23% – 26%
May 8, 2026 15% – 19% changed to Nov 6, 2026 23% – 26%
Outpatient Medical same-store NOI growth Lowered 0.5% – 1%
May 8, 2026 0% – 2% changed to Nov 6, 2026 0.5% – 1%
TripleNet Properties same-store NOI growth 2.5% – 3.5%
Previous outlook earlier release · from the 8-K filed Nov 5, 2026

Still-open targets the latest release did not restate under the same label.

Net income per diluted share · year ending December 31, 2026 $0.59 – $0.62
NAREIT FFO per diluted share · year ending December 31, 2026 $2.13 – $2.16
Total Portfolio SS NOI Growth · year ending December 31, 2026 12% – 14%
SHOP · year ending December 31, 2026 23% – 26%
Outpatient Medical · year ending December 31, 2026 0.5% – 1%
Triple-Net Leased Properties · year ending December 31, 2026 2.5% – 3.5%
ISHC · year ending December 31, 2026 14.5% – 16.5%
Total Portfolio Same-Store NOI Growth · Full Year 2026 12% – 14%
Guided vs delivered · last 1 settled
Net income per diluted share Full Year 2025
guided $0.47 – $0.50
$0.42 Miss −13.4%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+11% Bullish
Price vs 50-day avg
+8% Bullish
RSI (14)
63 Neutral
MACD trend
Positive Bullish
52-week position
88% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $53 › 200d $52 — 50d above 200d
Institutional flow Accumulating
515 of 579 funds reported for Sep 30 · net +26.9M sh shares · +57 new
Insider flow Distributing
Net -$226.4K over 90 days · 100% sells
Short interest Rising
14.51% of shares out · ▲ +1.5% MoM · 10.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
579 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $46 Now $58 · 88% Range high $59
vs 200-day avg +11% vs 50-day avg +8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
NAREIT FFO attributable to controlling interest non-GAAP 97.98M Three Months Ended June 30, 2026 filing —
Net operating income non-GAAP 137.24M Three Months Ended June 30, 2026 filing —
Normalized FFO attributable to controlling interest non-GAAP 105.19M Three Months Ended June 30, 2026 filing —
GAAP → non-GAAP reconciliation
NAREIT FFO attributable to controlling interest 97.98M (non-GAAP)
+2.79M Transaction, transition and restructuring costs
+300K Amortization of above- and below-market leases
+12K Amortization of closing costs — debt security investment
-354K Change in deferred rent
+5.77M Non-cash impact of changes to equity instruments
-223K Non-cash income tax benefit
-711K Capitalized interest
+147K Loss on debt extinguishments
-357K (Gain) loss in fair value of derivative financial instruments
-75K Foreign currency (gain) loss
+0K Adjustments for unconsolidated entities
-79K Adjustments for noncontrolling interests
= Normalized FFO attributable to controlling interest 105.19M
Segment net operating income non-GAAP $137.24M Three Months Ended June 30, 2026 filing —
Annualized Cash NOI non-GAAP 571.84M as of June 30, 2026 —
NAREIT FFO per common share attributable to controlling interest — diluted $0.99 Six Months Ended June 30, 2026 —
Normalized FFO per common share attributable to controlling interest — diluted non-GAAP $1.05 Six Months Ended June 30, 2026 —
Revenue per square foot $32.29 Q2 2026 —
RevPOR $5,754 Q2 2026 —
Same-Store NOI non-GAAP 219.32M Six Months Ended June 30, 2026 —
Same-Store properties non-GAAP 115 Q2 2026 —
Total average Occupancy 89.5% Q2 2026 —
Trailing 12-months Retention 65.2% as of June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

REIT - Healthcare Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AHR
American Healthcare REIT, Inc.
this stock
$13.41B +22.8% +9.1% 115.6 14.5%
WELL
Welltower Inc.
$179.34B +31.7% +35.6% 106.3 2.4%
VTR
Ventas, Inc.
$47.02B +14.9% +18.5% 167.8 2.8%
OHI
Omega Healthcare Investors Inc
$14.32B +6.1% +13.2% 18.9 4.8%
DOC
Healthpeak Properties, Inc.
$13.78B +24.3% +4.5% 37.0 3.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
601
% held
108.4%
Reported
515 of 579
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
468
View
Short & Settlement
Short Interest Rising
Shares short
33.7M
Days to cover
10.3d
Change
+501.8K sh
View
Short Volume
Short vol %
42%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
85
Value
$4.3K
As of
Oct 9, 2026
View
Off-Exchange
Off-exchange %
32.9%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$226.4K
Buyers / Sellers
0 / 2
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$2.3B
Net income (FY)
$69.8M
EPS diluted
$0.42
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 6, 2026
This year
31

American Healthcare REIT, Inc. reported nine-month 2026 revenue of $2,067,173 thousand, up from $1,656,043 thousand in 2025, driven by acquisitions and higher resident occupancy. As of September 30, 2026, its portfolio comprised 366 buildings totaling approximately 25,437,000 square feet.

View
Proposed Sales
Value
$97.1K
Shares
2.0K
Filed
Mar 25, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 6, 2026
View
Investor Relations
Latest news
American Healthcare REIT Announce…
Published
Nov 5, 2026
View

Performance

5D 20D 120D MTD YTD
AHR -0.2% +8.6% +13.3% +8.0% +22.8%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -2.8% +9.7% +12.8% +8.1% +12.2%

Capital returns

Latest dividend
$0.25 / share · ex Sep 30, 2026
Paid (TTM)
$1.00 / share · 4 payouts
Dividend yield (TTM, derived)
1.73%
Full dividend history

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1632970 CUSIP 398182303 13F (30d) 462 filings 427 filers Visit website Investor relations